If new information arises that changes risk/benefit, what should happen regarding consent?

If new information arises that changes risk/benefit, what should happen regarding consent?

• A. Notify regulatory authority only
• B. Continue without changes
• C. Re-consent the participants
• D. Update investigators only

Answer: (C)

Informed consent is an ongoing process. When new information emerges that changes the risk or benefit of participating, participants must be informed of those changes and given the opportunity to decide again whether to continue. This is why re-consenting the participants is the appropriate action. Re-consenting means presenting the new information in clear, understandable language, giving participants time to ask questions, and obtaining their voluntary agreement to continue under the updated risk/benefit terms. It ensures their autonomy is respected and that consent remains valid throughout the study. If re-consent cannot be obtained, the study may need to be paused or stopped for those participants, depending on the new information and ethics/regulatory guidance. Notifying a regulatory authority alone doesn’t address the participant’s informed decision-making; updating investigators without securing participant consent doesn’t document that participants agree to the new risk/benefit context; and continuing without changes ignores new information that could alter a participant’s willingness to stay in the trial.

Informed consent is an ongoing process. When new information emerges that changes the risk or benefit of participating, participants must be informed of those changes and given the opportunity to decide again whether to continue. This is why re-consenting the participants is the appropriate action.

Re-consenting means presenting the new information in clear, understandable language, giving participants time to ask questions, and obtaining their voluntary agreement to continue under the updated risk/benefit terms. It ensures their autonomy is respected and that consent remains valid throughout the study. If re-consent cannot be obtained, the study may need to be paused or stopped for those participants, depending on the new information and ethics/regulatory guidance.

Notifying a regulatory authority alone doesn’t address the participant’s informed decision-making; updating investigators without securing participant consent doesn’t document that participants agree to the new risk/benefit context; and continuing without changes ignores new information that could alter a participant’s willingness to stay in the trial.